Bronchoscopic Thermal Saline Ablation (BTSA) of Emphysematous Lung. A New Emphysema Therapy (BTSA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01920321|
Recruitment Status : Unknown
Verified August 2013 by Assaf-Harofeh Medical Center.
Recruitment status was: Recruiting
First Posted : August 12, 2013
Last Update Posted : August 12, 2013
Aim: To evaluate feasibility, safety and efficacy of relatively simple approach of bronchoscopic lung volume reduction (LVR) technology, independent of collateral ventilation.
Description: Patients with severe upper lobes heterogeneous emphysema, undergo unilateral bronchoscopic installation of saline thermal energy 50-55 ºC intending to induce an inflammatory airway and parenchymal injury and consequently fibrotic response resulting in LVR;
|Condition or disease||Intervention/treatment||Phase|
|Emphysema||Procedure: Endoscopic lung volume reduction||Phase 1 Phase 2|
- Age 40-75 unlimited sex. 20 subjects
- chronic obstructive pulmonary disease (COPD), GOLD 3-4 (global obstructive lung disease).
- CT scan of lung and included high resolution slices. Demonstrating emphysematous, bullotic changes in the upper lobes.
- Pulmonary function tests results- total lung capacity(TLC)>110%, residual volume(RV)>150%, diffusion of lung CO(DLCO)<80%,forced expiratory volume 1 second(FEV1):15-45%.
- 6 minute walking distance (6MWD)> 140 meters.
- Active ischemic heart disease, significant arrhythmia. ejection fraction (EF) <40%.
- COPD that cause carbon bioxide(CO2) retention above 50 mm Hg and / or oxygen saturation at rest below 88%.
- Pulmonary hypertension> 45 mmHg, according to the Echo Test.
- . Cancer treatment with chemotherapy / radiation or expected life expectancy of less than two years.5. Pregnancy.
Methods: . A. Patient preparation and sedation as in diagnostic bronchoscopy. Sedation will be based on midzoln + demerol. The patients will be treated prior the treatment with Inhalation with salbutamol ans ipratropium bromide. Flexible bronchoscope with outer diameter 5 mm is introduced to the targated upper lobe, and placed in wedged position. This is followed by installion of 0.9% natriu, chloride(NaCl) at a temperature of 55ºC exit temperature 50ºC) in portions of 40 ml to 200 ml (in bronchoalveolar lavage up to 300 ml is acceptable. The patient is placed in horizontal position, and continuous ECG blood pressure. Oxygen saturation are monitored. This monitoring will be continue at least 2 hours after treatment. A chest x-ray is followed and the patient remain in the department for overnight.
Tracking: Minimum of 6 months - Outpatient follow up include in addition to physical examination extended pulmonary function test and after 3-6 months. low radiation chest CT.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Lung Volume Reduction in COPD Patients With an Inhomogeneous Severe Emphysema Located in the Upper Lobes, by Injecting Warm Saline Through the Bronchoscope Channel|
|Study Start Date :||February 2013|
|Estimated Primary Completion Date :||June 2014|
|Estimated Study Completion Date :||December 2014|
Experimental: Endoscopic lung volume reduction
After usual sedation, bronchoscope is introduce to the lung and palced in segmental wedge position then hot salineis instilled. Same procedure to others affected segments.
Procedure: Endoscopic lung volume reduction
Prior the procedure patients undergo - high resolution chest CT , extensive phisiological assessment.
- Pulmonary function improvemnt [ Time Frame: 6 months ]Clinical - COPD assessment test (CAT ) + lung volumes + diffusion capaciry and 6MWD .
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01920321
|Contact: David Stav, MD||972- firstname.lastname@example.org|
|Contact: Isaac Shpirer, MD||972- 89779024|
|Assaf Harofeh Medical Center||Recruiting|
|Beer Yaakov, Israel, 70300|
|Principal Investigator: David Stav, MD|
|Principal Investigator:||david Stav, MD||Assaf-Harofeh Medical Center|